Cassava Sciences, Inc. (SAVA) financial statements (2020 and earlier)
Company profile
| Business Address |
7801 N CAPITAL OF TEXAS HIGHWAY AUSTIN, TX 78731 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 23 | 20 | 10 | 19 | 31 | 41 | 50 | ||
| Cash and cash equivalents | 23 | 20 | 10 | 17 | 31 | 41 | 49 | ||
| Short-term investments | 2 | 1 | |||||||
| Other undisclosed cash, cash equivalents, and short-term investments | (0) | (0) | |||||||
| Other current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed current assets | 0 | 0 | |||||||
| Total current assets: | 23 | 20 | 11 | 19 | 32 | 41 | 50 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Other noncurrent assets | 0 | 0 | 0 | 0 | |||||
| Other undisclosed noncurrent assets | 0 | ||||||||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 0 | 0 | |||
| TOTAL ASSETS: | 23 | 20 | 11 | 19 | 32 | 41 | 50 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1 | 1 | 1 | 1 | 3 | 1 | 1 | ||
| Accounts payable | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Accrued liabilities | 1 | 0 | 0 | 0 | 1 | ||||
| Employee-related liabilities | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||
| Other liabilities | 0 | ||||||||
| Other undisclosed current liabilities | 0 | 0 | 1 | ||||||
| Total current liabilities: | 1 | 1 | 1 | 1 | 3 | 1 | 2 | ||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 1 | 1 | 1 | 1 | 3 | 1 | 2 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 22 | 20 | 10 | 19 | 29 | 40 | 48 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 191 | 184 | 167 | 164 | 160 | 157 | 152 | ||
| Accumulated other comprehensive income | 0 | 0 | |||||||
| Accumulated deficit | (169) | (164) | (157) | (145) | (131) | (116) | (104) | ||
| Total stockholders' equity: | 22 | 20 | 10 | 19 | 29 | 40 | 48 | ||
| TOTAL LIABILITIES AND EQUITY: | 23 | 20 | 11 | 19 | 32 | 41 | 50 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 41 | |||||||
| Operating expenses | (5) | (7) | (12) | (15) | (14) | (12) | (10) | |
| Operating income (loss): | (5) | (7) | (12) | (15) | (14) | (12) | 31 | |
| Income (loss) from continuing operations before equity method investments, income taxes: | (5) | (7) | (12) | (15) | (14) | (12) | 31 | |
| Other undisclosed income from continuing operations before income taxes | 0 | 0 | 0 | |||||
| Income (loss) from continuing operations before income taxes: | (5) | (7) | (12) | (15) | (14) | (12) | 31 | |
| Income tax benefit | 0 | |||||||
| Net income (loss): | (5) | (7) | (12) | (15) | (14) | (12) | 32 | |
| Other undisclosed net income attributable to parent | 0 | 0 | 0 | 0 | ||||
| Net income (loss) available to common stockholders, diluted: | (5) | (7) | (12) | (15) | (14) | (12) | 32 | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (5) | (7) | (12) | (15) | (14) | (12) | 32 | |
| Other comprehensive loss | (0) | (0) | ||||||
| Comprehensive income (loss): | (5) | (7) | (12) | (15) | (14) | (12) | 32 | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 0 | 0 | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (5) | (7) | (12) | (15) | (14) | (12) | 32 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.